comprehensive -WSS

comprehensive

author：focus 2025-10-04 11:35:55 - browse：52947

Jacob S. Van Naarden (left), Athena Countouriotis( center), and Vlad Coric (right) on stage at the 2023 STAT Summit. — From left, Eli Lilly's Jacob S. Van Naarden, Avenzo's Athena Countouriotis, and Biohaven's Vlad Coric on stage at the 2023 STAT Summit. STAT

What does it feel like to run a biotech startup and then get “the call” — the one from the big pharma CEO who wants to acquire your company for billions of dollars?

At the 2023 STAT Summit on Wednesday, senior biotech writer Adam Feuerstein posed this question to three people very qualified to answer it: Vlad Coric, chairman and CEO of Biohaven, which was acquired by Pfizer in 2022 for $11.6 billion; Jacob Van Naarden, former COO of Loxo Oncology, which was acquired by Eli Lilly (where Van Naarden is now executive vice president) for $8 billion in 2019; and Athena Countouriotis, whose company Turning Point Therapeutics was acquired by BMS for $4 billion in 2022.

“Imagine you’re going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o’clock tonight,” said Coric, whose company had a successful migraine drug on the market and had just completed an IPO at the time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： FDA drug safety: Singulair case shows systemic surveillance flaws

WSS

Vertigo drug brings hope for rare neuron disorder, Niemann

Even great ERs can’t make up for American health disparities

The health care issue Democrats can’t solve: hospital reform

Congressmen charge Covid hearing ‘could have been an email’

Covid misinformation case heads to Supreme Court

Woodcock on FDA’s accelerated approval and her next chapter

focus

comprehensive

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

Time to name cancers by genetics, not organ of origin, expert says

DIEP, the 'gold standard' of breast reconstruction, is under threat

What is microchimerism and how does it affect maternal health?

Supreme Court strikes down use of affirmative action

Medicare drug price negotiation’s day in court

DIEP, the 'gold standard' of breast reconstruction, is under threat

New Ultima Genomics DNA sequencer can read genome for $100

Medicare details structure of new drug price negotiation program

After Sarepta trial failure, Duchenne families brace for more debate

explore

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Some dementia cases could be undiagnosed liver disease

Explaining an after

Explaining an after

Explaining an after

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

focus

focus

entertainment

Wikipedia